Werewolf Therapeutics, Inc.
HOWL
$0.39
$0.001.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.00M | -- | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.00M | -- | -- | 0.00 | 0.00 |
| Cost of Revenue | 26.19M | 33.91M | 41.73M | 50.48M | 51.26M |
| Gross Profit | -5.19M | -33.91M | -41.73M | -50.48M | -51.26M |
| SG&A Expenses | 20.39M | 17.74M | 18.95M | 21.13M | 21.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.57M | 51.65M | 60.68M | 71.61M | 73.01M |
| Operating Income | -25.57M | -51.65M | -60.68M | -71.61M | -73.01M |
| Income Before Tax | -34.61M | -56.27M | -60.82M | -72.84M | -73.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.61 | -56.27 | -60.82 | -72.84 | -73.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.61M | -56.27M | -60.82M | -72.84M | -73.14M |
| EBIT | -25.57M | -51.65M | -60.68M | -71.61M | -73.01M |
| EBITDA | -21.92M | -50.05M | -59.04M | -69.93M | -71.28M |
| EPS Basic | -0.73 | -1.21 | -1.33 | -1.62 | -1.64 |
| Normalized Basic EPS | -0.34 | -0.70 | -0.83 | -1.01 | -1.03 |
| EPS Diluted | -0.76 | -1.24 | -1.36 | -1.62 | -1.64 |
| Normalized Diluted EPS | -0.34 | -0.70 | -0.83 | -1.01 | -1.03 |
| Average Basic Shares Outstanding | 191.42M | 187.81M | 184.04M | 180.09M | 177.99M |
| Average Diluted Shares Outstanding | 192.22M | 188.60M | 184.83M | 180.09M | 177.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |